Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
par Tripathy, Debu;Body, Jean-Jacques ;Bergström, Bengt
Référence Clinical therapeutics, 26, 12, page (1947-1959)
Publication Publié, 2004-12
Référence Clinical therapeutics, 26, 12, page (1947-1959)
Publication Publié, 2004-12
Article révisé par les pairs
Résumé : | Metastatic bone disease is a serious clinical problem in patients with advanced cancer. Bisphosphonates inhibit the activity of osteoclasts and are the treatment of choice for bone metastases. |